NuCana (NCNA) Surges: Stock Moves 6.3% Higher
NuCana plc NCNA was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $4.57–$5.69 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
NuCana currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
NuCana PLC Sponsored ADR Price
NuCana PLC Sponsored ADR price | NuCana PLC Sponsored ADR Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Emergent BioSolutions Inc. EBS, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
NuCana PLC Sponsored ADR (NCNA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
